Sunlight, vitamin D and prostate cancer epidemiology

Vitamin D

Volumn , Issue , 2011, Pages 965-978

  Schwartz, Gary G ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84555207484     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-381978-9.10053-8     Document Type: Chapter

References (117)

1. Schwartz G.G., Hulka B.S. Is vitamin D deficiency a risk factor for prostate cancer (Hypothesis)?. Anticancer Res. 1990, 10:1307-1311.
2. Schwartz G.G. Vitamin D and intervention trials in prostate cancer: from theory to therapy. Ann. Epidemiol. 2009, 19:96-102.
3. Beer T.M., Myrthue A. Calcitriol in the treatment of prostate cancer. Anticancer Res. 2006, 26:2647-2651.
4. Lagunova Z., Porojnicu A.C., Dahlback A., Berg J.P., Beer T.M., Moan J. Prostate cancer survival is dependent on season of diagnosis. Prostate 2007, 67:1362-1370.
5. Robinson W.S. Ecological correlations and the behavior of individuals. Am. Sociol. Rev. 1950, 15:351-357.
6. Schwartz G.G., Porta M. Vitamin D, ecologic studies and endometrial cancer. Prev. Med. 2007, 45:323-324.
7. Ernster V.L. Nested case-control studies. Prev. Med. 1994, 23:587-590.
8. Cancer Mortality Statistics in the World, 1950-1985 1989, University of Nagoya Press, Nagoya, Japan. M. Kurihara, K. Aoki, S. Hismamichi (Eds.).
9. Yatani R., Chigusa I., Akazaki K., Stermmerman G., Welsh R., Correa P. Geographic pathology of latent prostate carcinoma. Int. J. Cancer 1984, 29:611-616.
10. Sakr W.A., Haas G.P., Cassin B.F., Pontes J.E., Crissman J.D. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young adult patients. J. Urol. 1993, 150:379-385.
11. Breslow N., Chan C.W., Dhom G., Drury R.A., Franks L.M., Gellei B., et al. Latent carcinoma of the prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int. J. Cancer 1977, 20:379-385.
12. Lin K., Lipsitz R., Miller T., Janakiraman S., U.S.Preventive Services Task Force Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force. Ann. Intern. Med. 2008, 149:192-199.
13. Andriole G.L., Grubb R.L., Buys S.S., Chia D., Church T.R., Fouad M.N., et al. PLCO Project Team, Mortality results from a randomized prostate-cancer screening trial. New Engl. J. Med. 2009, 360:1310-1319.
14. Etzioni R., Cha R., Feurer E.J., Davidov O. Asymptomatic incidence and duration of prostate cancer. Am. J. Epidemiol. 1998, 148:775-785.
15. Hanchette C.L., Schwartz G.G. Geographic patterns of prostate cancer mortality: evidence for a protective effect of ultraviolet radiation. Cancer 1992, 70:2861-2869.
16. Schwartz G.G., Hanchette C.L. UV, latitude, and prostate cancer mortality: all sunlight is not the same. (United States) Cancer Causes Control 2006, 17:1091-1101.
17. 3. Cancer Res. 1992, 52:515-520.
18. Skowronski R.J., Peehl D.M., Feldman D. Vitamin D and prostate cancer: 1,25-dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinol. 1993, 132:1952-1960.
19. Moreno J., Krishnan A.V., Feldeman D. Molecular mechanisms mediating the anti-proliferative effects of vitamin D in prostate cancer. J. Steroid Biochem. Bol. Biol. 2005, 97:31-36.
20. Schwartz G.G., Wang M.-H., Zhang M., Singh R.K., Siegal G.P. 1α, 25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidem. Biomarkers Prev. 1997, 6:727-732.
21. 3 decreases human prostate cancer cell adhesion and migration. Mol. Cell Endocrinol. 2000, 164:133-143.
22. Lokeshwar B.L., Schwartz G.G., Selzer M.G., Burnstein K.L., Zhuang S-H., Block N.L., et al. Inhibition of prostate cancer metastasis in vivo: A comparison of 1,25-Dihydroxyvitamin D (calcitriol) and EB1089. Cancer Epidem. Biomarkers Preven. 1999, 8:241-248.
23. 3 inhibits prostate cancer cell invasion via modulation of selective proteases. Carcinogenesis 2006, 27:32-42.
24. 3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis. Carcinogenesis 2007, 27:1883-1889.
25. Haddad J.G., Hahn T.J. Natural and synthetic sources of circulating 25-hydroxyvitamin D in man. Nature 1973, 244:525-527.
26. M.F. Holick Photobiology of vitamin D. in: D. Feldman, F.H. Gloriexux, J.W. Pike, (Eds.), Vitamin D, first ed., San Diego, CA: Academic Press, 33-39.
27. Chesney R.W., Rosen J.F., Hanstra A.J., Smith C., Mahaffey K., DeLuca H.F. Absence of seasonal variations in serum concentrations of 1,25-dihydroxyvitamin D despite a rise in 25-hydroxyvitamin D in summer. J. Clin. Endocrinol. Metab. 1981, 53:139-143.
28. 3. Cancer Epidemiol. Biomarkers Prev. 1998, 7:391-395.
29. 3, inhibits the proliferation of primary prostatic epithelial cells. Cancer Epidemiol. Biomarkers Prev. 2000, 9:265-270.
30. Young M.V., Schwartz G.G., Wang L., Jamieson D.P., Whitlatch L.W., Flanagan J.N., et al. The prostate 25-hydroxyvitamin D-1?-hydroxylase is not influenced by parathyroid hormone and calcium: implications for prostate cancer chemoprevention by vitamin D. Carcinogenesis 2004, 25:967-971.
31. 3-induced growth inhibition. Cancer Res. 2001, 61:2852-2856.
32. Whitlatch L.W., Young M.V., Schwartz G.G., Flanagan J.N., Burnstein K.L., Lokeshwar B.L., et al. 25-Hydroxyvitamin D-1-alpha-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer. J. Steroid Biochem. Mol. Biol. 2002, 81:135-140.
33. 2 as therapeutic agents for prostate cancer. Clin. Cancer Res. 2000, 6:901-908.
34. Haussler M.R., Jurutka P.W., Hseih J.C., Thompson P.D., Selznick S.H., Haussler C.A., et al. New understanding of the molecular mechanism of receptor-mediated genomic actions of vitamin D hormone. Bone 1995, 17:33S-38S.
35. Zhuang S.-H., Schwartz G.G., Cameron D., Burnstein K.L. Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cells. Mol. Cell Endocrin. 1997, 126:83-90.
36. 3 in seven human prostatic carcinoma cell lines. Clin. Cancer Res. 1995, 1:997-1003.
37. Kivineva M., Bläuer M., Syvälä H., Tammela T., Tuohimaa P. Localization of 1,25-Dihydroxyvitamin D3 receptor (VDR) expression in human prostate. J. Steroid Biochem. Molec. Biol. 1998, 66:121-127.
38. Blutt S.E., Weigel N.L. Vitamin D and prostate cancer. Proc. Soc. Exp. Biol. Med. 1999, 221:89-98.
39. Miller G.J. Vitamin D and prostate cancer: biological interactions and clinical potentials. Cancer Metastasis Rev. 1998, 17:353-360.
40. Schwartz G.G. Vitamin D and the epidemiology of prostate cancer. Semin. Dial. 2005, 19:276-289.
41. Chan J.M., Giovannucci E., Andersson S.O., Yuen J., Adami H.O., Wolk A. Dairy products, calcium, phosphorus, vitamin D, and risk of prostate cancer (Sweden). Cancer Causes Control 1998, 9:559-566.
42. Kristal A.R., Cohen J.H., Qu P., Stanford R. Associations of energy, fat, calcium and vitamin D with prostate cancer risk. Cancer Epidemiol. Biomarkers Prev. 2002, 11:719-725.
43. Kristal A.R., Arnold K.B., Neuhouser M.L., Goodman P., Platz E.A., Albanes D., et al. Diet, supplement use, and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Am. J. Epidemiol. 2010, 17:556-577.
44. Kafadar K. Geographic trends in prostate cancer mortality: an application of spatial smoothers and the need for adjustment. Ann. Epidemiol. 1997, 7:35-45.
45. Grant W.B. An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. Cancer 2002, 94:1867-1875.
46. Bosco F.P., Schymura M.J. Solar ultraviolet-B exposure and cancer incidence and mortality in the United States, 1993-2002. BMC. Cancer 2006, 10:264.
47. St-Hilaire S., Mannel S., Commendador A., Mandal R., Derryberry D. Correlations between meteorologic parameters and prostate cancer. Int. J. Health Geographics 2010, 9:19.
48. Mandal R., St- Hilaire S., Kie J.G., Derryberry D. Spatial trends of breast and prostate cancers in the United States between 2000 and 2005. Int. J. Health Geographics 2009, 8:53. doi: 10.1186/1467-072X-8-53.
49. Webb A.R., Kline L., Holick M.F. Influence of season and latitude on the cutaneous synthesis of vitamin D3. Exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J. Clin. Endocrinol. Metab. 1988, 67:373-378.
50. Uitterlinden A.G., Fang Y., Van Meurs J.B.J., Pols H.A., Van Leeuwen J.P. Genetics and biology of vitamin D receptor polymorphisms. Gene 2004, 338:143-156.
51. Raimondi S., Johansson H., Maisonneuve P., Gandini S. Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Carcinogenesis 2009, 30:1170-1180.
52. Ahn J., Albanes D., Berndt S.I., Peters P., Chatterjee N., Freedman N.D., et al. Prostate, Lung, Colorectal, Ovarian Trial, Project Team, Vitamin D-related genes, serum vitamin D concentrations and prostate cancer risk. Carcinogenesis 2009, 30:769-776.
53. Yin M., Wei S., Wei Q. Vitamin D receptor genetic polymorphisms and prostate cancer risk: a meta-analysis of 36 published studies. Int. J. Clin. Exp. Med. 2009, 15:159-175.
54. Köstner K., Denzer N., Müller C.S., Klein R., Tilgen W., Reivhrath J. The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer:. a review of the literature Anticancer Res. 2009, 29:3511-3536.
55. Taylor J.A., Hirvonen A., Watson M., Pittman G., Mohler J.L., Bell D.A. Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res. 1996, 56:4108-4110.
56. Ingles S.A., Ross R.K., Yu M.C., Irvine R.A., La Pera G., Haile R.W., et al. Association of prostate cancer with genetic polymorphisms in vitamin D receptor and androgen receptor. J. Natl. Cancer Inst. 1997, 89:166-170.
57. Ntais C., Polycarpou A., Ioannidid J.P. Vitamin D receptor gene polymorphisms and risk of prostate cancer: a meta-analysis. Cancer Epidemiol. Biomarkers Prev. 2003, 12:1395-1402.
58. John E.M., Schwartz G.G., Koo J., Van Den Berg D., Ingles S.A. Solar exposure, vitamin D gene polymorphisms and risk of advanced prostate cancer. Cancer Res. 2005, 65:5470-5479.
59. Bodiwala D., Luscombe C.J., French M.E., Liu S., Saxby M.F., Jones P.W., et al. Polymorphisms in the vitamin D receptor gene, ultraviolet radiation, and susceptibility to prostate cancer. Environ. Mol. Mutagen 2004, 43:121-127.
60. Ma J., Stampfer M.J., Gann P.H., Hough H.L., Giovannucci E., Kelsey K.T., et al. Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians. Cancer Epidemiol. Biomarkers Prev. 1998, 7:385-390.
61. Li H., Stampfer M.J., Hollis J.B., Mucci L.A., Gaziano J.M., Hunter D., et al. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med. 2007, 4:e103.
62. Mikhak B., Hunter D.J., Spiegelman D., Platz E.A., Hollis B.W., Giovannucci E. Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25-hydroxyvitamin D and 1,25-dihydroxyitamin D, and prostate cancer risk. Prostate 2007, 67:911-923.
63. Hamasaki T., Inatomi H., Katoh T., Matsumoto T. Significance of vitamin D receptor gene polymorphism for risk and disease severity of prostate cancer and benign prostatic hyperplasia in Japanese. Urol. Int. 2002, 68:226-231.
64. Holt S.K., Kwon E.M., Koopmeiners J.S., Lin D.W., Feng Z., Ostrander E.A., et al. Vitamin D pathway gene variants and prostate cancer prognosis. Prostate. DOI. 10.1002/pros.21180 2010.
65. Gandini S., Boniot M., Haukka J., Byrnes G., Cox B., Sneyd M.J., et al. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int. J. Cancer, epub ahead of print 2010.
66. Yin H., Raum E., Haug U., Arndt V., Brenner H. Meta-analysis of longitudinal studies: serum vitamin D and prostate cancer risk. Cancer Epidemiol. 2009, 33:435-445.
67. Corder E.H., Guess H.A., Hulka B.S., Friedman G.D., Sadler M., Vollmer R.T., et al. Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol. Biomarkers Prev. 1993, 2:467-472.
68. Ahonen M.H., Tenkanen L., Teppo L., Hakama M., Tuohimaa P. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 2000, 11:847-852.
69. Nomura A.M., Stemmermann G.N., Lee J., Kolonel L.N., Chen T.C., Turner A., et al. Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States). Cancer Causes Control 1998, 9:425-432.
70. Braun M.M., Helzlsouer K.J., Hollis B.W., Comstock G.W. Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States). Cancer Cause Control 1995, 9:425-432.
71. Jacobs E.T., Giuliano A.B., Martinez M.E., Hollis B.W., Reid M.E., Marshall J.R. Plasma levels of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and the risk of prostate cancer. J. Steroid Biochem. Mol. Biol. 2004, 89-90:533-537.
72. Gann P.H., Ma J., Hennekens C.H., Hollis B.W., Haddad J.G., Stampfer M.J. Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 1996, 5:121-126.
73. Platz E.A., Leitzmann M.F., Hollis B.W. Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control 2004, 15:255-265.
74. Barnett C.M., Nielson C.M., Shannon J., Chan J.M., Shikany J.M., Bauer D.C., et al. Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men. Cancer Causes Control 2010, DOI.1007/s.10552-010-9557-y.
75. Park S.-Y., Cooney R.V., Wilkens L.R., Murphy S.P., Henderson B.E., Kolonel L.N. Plasma 25-hydroxyvitamin D and prostate cancer risk: the Multinethnic Cohort. Eur. J. Cancer 2010, 46:932-936.
76. Holick M.F. Vitamin D deficiency. New Engl. J. Med. 2007, 357:266-281.
77. Tuohimaa P., Tenkanen L., Ahonen M., Lumme S., Jellum E., Hallmans G., et al. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int. J. Cancer 2004, 108:104-108.
78. Ahn J., Peters U., Albanes D., Purdue M.P., Abnet C.C., Chaterjee N., et al. Prostate, Lung, Colorectal, Ovarian Screening Trial Project Team, Serum vitamin D concentrations and prostate cancer risk: a nested case-control study. J. Natl. Cancer Inst. 2008, 100:796-804.
79. Travis R.C., Crowe F.L., Ellen N.E., Appleby P.N., Roddam A.W., Tjønneland A., et al. Serum vitamin D and risk of prostate cancer in a case-control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC). Am. J. Epidemiol. 2009, 169:1223-1232.
80. Tretli S., Hernes E., Berg J.P., Hestvik U.E., Tobsahm T.E. Association between serum 25(OH)D and death from prostate cancer. Br. J. Cancer 2009, 100:450-454.
81. Luscombe C.J., Fryer A.A., French M.F., Liu S., Saxby M., Jones P.W., et al. Exposure to ultraviolet radiation: association with susceptibility and age at presentation with prostate cancer. Lancet 2001, 358:641-642.
82. Luscombe C.J., French M.E., Siu S., Saxby M.R., Jones P.W., Fryer A.A., et al. Prostate cancer risk: associations with ultraviolet radiation, tyrosinase and melanocortin-1 receptor genotypes. Br. J. Cancer 2001, 85:1504-1509.
83. Rukin N., Blagojevic M., Luscombe C.J., Liu S., Saxby M., Ramachandran S., et al. Associations between timing of exposure to ultraviolet radiation, T-stage and survival in prostate cancer. Cancer Detect Prevent 2007, 31:443-449.
84. Walsh P.C., Worthington J.F. The Prostate: A Guide for Men 1995, Johns Hopkins University Press, Baltimore, MD.
85. Freedman D.M., Dosemeci M., McGlynn K. Sunlight and mortality from breast, ovarian, colon, prostate, and non-melanoma skin cancer: a composite death certificate based case-control study. Occup. Environ. Med. 2002, 59:257-262.
86. Weinrich S., Ellison G., Weinrich M., Ross K., Reis-Starr C. Low sun exposure and elevated serum prostate specific antigen in African American and Caucasian men. Am. J. Health Studies 2001, 17:148-150.
87. John E.M., Dreon D.M., Koo J., Schwartz G.G. Residential sunlight exposure is associated with a decreased risk of prostate cancer. J. Steroid Biochem. Mol. Biol. 2004, 89-90:549-552.
88. Giovannucci E., Liu Y., Rimm E.B., Hollis B.W., Fuchs C.S., Stampfer M.J., et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. JNCI 2006, 98:451-459.
89. Robsahm T.E., Tretli S., Dahlback A., Moan J. Vitamin D3 from sunlight may improve the prognosis of breast-, colon- and prostate cancer (Norway). Cancer Causes Control 2004, 15:149-158.
90. de Vries D., Soerjomataram I., Houterman S., Louwnam M.W., Coebergh J.W. Decreased risk of prostate cancer after skin cancer diagnosis: a protective role of ultraviolet radiation?. Am. J. Epidemiol. 2007, 165:966-972.
91. Levi F., Randimbison L., Te V.-C., Concono M.M., La Vecchia C. Risk of prostate, breast and colorectal cancer after skin cancer diagnosis. Int. J. Cancer 2008, 123:2899-2901.
92. Gilbert R., Metcalfe C., Oliver S.E., Whiteman D.G., Barin C., Ness A., et al. Life course sun exposure and risk of prostate cancer: population-based nested case-control study and meta-analysis. Int. J. Cancer 2009, 15:1414-1423.
93. Schwartz G.G. The "Cocaine Blues" and other problems in epidemiologic studies of vitamin D and cancer. Nutrition Reviews 2007, 65:S75-S76.
94. Rose D.P., Boyar A.P., Wynder E.L. International comparisons of mortality rates for cancer of the breast, ovary, prostate, and colon, and per capita food consumption. Cancer 1986, 58:2363-2371.
95. Parodi P.W. Dairy product consumption and the risk of prostate cancer. Int. Dairy J. 2009, 19:551-565.
96. World Cancer Research Fund/American Institute for Cancer Research Food, nutrition, physical activity, and the prevention of cancer: A global perspective 2007, AICR, Washington, DC.
97. Agency for Health Care Research and Quality Vitamin D and calcium: a systematic review of health outcomes 2009, AHHRQ Publication No. 09-E015. http://www.ahrq.gov/clinic/tp/vitadcaltp.htm.
98. Straub D.S. Calcium supplementation in clinical practice: a review of forms, doses, and indications. Nutr. Clinical Pract. 2007, 22:286-296.
99. Berndt S.I., Carter H.B., Landis P.K., Tucker M.L., Hsieh L.J., Metter E.J., et al. Baltimore Longitudinal Study of Aging, Calcium intake and prostate cancer risk in a long-term aging study: the Baltimore Longitudinal Study of Aging. Urology 2002, 60:1118-1123.
100. Giovannucci E., Lui Y., Stampfer M.J., Willett W.C. A prospective study of calcium intake and incidence of fatal prostate cancer. Cancer Epidemiol. Biomarkers Prev. 2006, 15:203-210.
101. Tseng M., Giri V., Watkins-Bruner D., Giovannucci E. Dairy intake and 1,25-dihydroxyvitamin D levels in men at high risk for prostate cancer. Cancer Causes Control 2009, 20:1947-1954.
102. Skinner H.G., Schwartz G.G. Serum calcium and incident and fatal prostate cancer in the National Health and Nutrition Examination Survey. Cancer Epidemiol. Biomarkers Prev. 2008, 17:2302-2305.
103. Skinner H.G., Schwartz G.G. A prospective study of total and ionized serum calcium and fatal prostate cancer. Cancer Epidemiol. Biomarkers Prev. 2009, 18:575-578.
104. Buchs N., Bonjour J.-P., Rizzoli R. Renal tubular absorption of phosphate is positively related to the extent of bone metastatic load in patients with prostate cancer. J. Clin. Endocrinol. Metab. 1998, 83:1535-1541.
105. Murray R.M.L., Grill V., Crinis N., Ho P.W.M., Davison J., Pitt P. Hypocalcemic and normocalcemic hyperparathyroidism in patients with advanced prostatic cancer. J. Clin Endocrinol. Metab. 2001, 86:511-516.
106. Flores S.Q., Varsavsky M., Valle Díaz De La Guardia F., Ortiz J.L.M., Torres M.M., Álvarez E.R., et al. Hiperparatiroidismo secundario en el cancer de próstata avanzado. Endocrinología y Nutrición 2010, 57:100-104.
107. Schwartz G.G. Prostate cancer, serum parathyroid hormone and the progression of skeletal metastases. Cancer Epidemiol. Biomarkers Prev. 2008, 17:478-483.
108. Lin K.I., Chattopadhyay N., Bai M., Alvarez R., Dang C.V., Baraban J.M., et al. Elevated extracellular calcium can prevent apoptosis via the calcium-sensing receptor. Biochem. Biophys. Res. Commun. 1998, 249. 325-310.
109. Lallet-Daher H., Roudbaraki M., Bavencoffee A., Mariot P., Gackière F., Bidaux G., et al. Intermediate-conductance Ca2+-activated K+ channels (IKca1) regulate human prostate cancer cell proliferation through a close control of calcium entry. Oncogene. online publication 9 March 2009, doi:10.1038/onc.2009.25.
110. Liao J., Schneider A., Datta N.S., McKauley L.K. Extracellular calcium as a candidate mediator of prostate cancer skeletal metastasis. Cancer Res. 2006, 77:9065-9073.
111. Schwartz G.G. Is serum calcium a biomarker of fatal prostate cancer?. Future Oncology 2009, 5:577-580.
112. Jorde R., Sundsfjord J., Bønaa K.H. Determinants of serum calcium in men and women. The Tromsø Study. Eur. J. Epidemiol. 2001, 17:1117-1123.
113. Patel A.M., Goldfarb S. Got calcium? Welcome to the Calcium-Alkali Syndrome. J. Am. Soc. Nephrol. 2010, doi: 10.1681/ASN.2010030255.
114. Kato Y., Sato K., Sata A., Omori K., Nakahima K., Tokinaga K., et al. Hypercalcemia induced by excessive intake of calcium supplements, presenting similar findings of primary hyperparathyroidism. Endocrine J. 2004, 51:557-562.
115. Muldowney W.P., Mazbar S.A. Rolaids-yogurt syndrome: a 1990s version of milk-alkali syndrome. Am. J. Kidney Dis. 1996, 27:270-272.
116. Skinner H.G., Schwartz G.G. The relation of serum parathyroid hormone and serum calcium to serum levels of prostate specific-antigen: a population-based study. Cancer Epidemiol. Biomarkers Prev. 2009, 11:2869-2873.
117. Engel P., Fagherazzi G., Boutten A., Dupré T., Mesrine S., Bouton-Ruault M.C., et al. Serum 25(OH)D and risk of breast cancer: a nested case-control study from the French E3N cohort. Cancer Epidemiol. Biomarkers Prev. 2010, 19:2341-2350.